LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming B. Riley Virtual Healthcare Conference on January 18th. The fireside chat will take place at 3:00 p.m. ET on January 18th. To access this event, please RSVP to your B. Riley Securities sales representative. Follow ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of (I.R.S. E ...

Agenus Inc. (NASDAQ:AGEN) Q3 2023 Earnings Conference Call November 7, 2023 9:00 AM ET Company Participants Zack Armen - Head, IR Dr. Garo H. Armen - Chairman & CEO Dr. Steven O'Day - CMO Todd Yancey - Chief Strategic Advisor Christine Klaskin - VP, Finance and Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - HC Wainwright Colleen Kusy - RW Baird Mayank Mamtani - B. Riley FBR Unidentified Analyst - Jefferies Operator Good morning. My name is Janie and I will be your con ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of (I.R.S. Employ ...

Agenus Inc. (NASDAQ:AGEN) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Zack Armen - Head, IR Dr. Garo Armen - Chairman & CEO Dr. Steven O'Day - Chief Medical Officer Christine Klaskin - Vice President of Finance Conference Call Participants Emily Bodnar - H.C. Wainwright Mike King - EF Hutton Mayank Mamtani - B. Riley Matt Phillips - William Blair Operator Good day, and welcome to the Agenus First Quarter 2023 Financial Results Conference Call. All lines have been placed on m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of (I.R.S. Emplo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of (I.R.S. Employer i ...

Agenus Inc. (NASDAQ:AGEN) Q4 2022 Results Conference Call March 14, 2023 8:30 AM ET Company Participants Zack Armen - Head, Investor Relations Dr. Garo Armen - Chairman and Chief Executive Officer Dr. Steven O'Day - Chief Medical Officer Christine Klaskin - Vice President of Finance Conference Call Participants Matt Phillips - William Blair Mayank Mamtani - B. Riley Emily Bodnar - H.C. Wainwright Mike King - EF Hutton David Dai - SMBC Kelly Shi - Jefferies Operator Thank you for holding and welcome, everyon ...

d Q January 2023 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus', MiNK's, and SaponiQx's clinical development and regulatory plans (including the scope of any regulatory approval and the ability to obtain priority review) and timelines for product candidates including balstilimab, zalifrelimab, botensilimab, AGEN1327, AGEN1777, AGEN2373, AGEN1571, and A ...

Agenus Inc. (NASDAQ:AGEN) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Nico Frelick - Investor Relations Dr. Garo Armen - Chairman and Chief Executive Officer Christine Klaskin - Vice President of Finance Dr. Steven O'Day - Chief Medical Officer Dhan Chand - Scientific Director, Head of Drug Discovery Conference Call Participants David Dye - SNBC Matt Phipps - William Blair Mayank Mamtani - B. Riley Securities Kelly Shi - Jefferies Operator Thanks for holding, and welcome ...